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Aim To determine whether the promoter polymorphism 
-203A>C of cholesterol-7α-hydroxylase encoding gene (CY-
P7A1) affects diurnal variation in CYP7A1 enzyme activity.
Methods The study included 16 healthy male volunteers – 
8 homozygous for -203A and 8 homozygous for the -203C 
allele of CYP7A1. Three 15-hour examinations (from 7am 
to 10pm) were carried out for each of the participants: af-
ter one-day treatment with cholestyramine; after one-day 
treatment with chenodeoxycholic acid (CDCA); and a con-
trol examination without any treatment. The plasma con-
centration of 7α-hydroxy-4-cholesten-3-one (C4), a marker 
of CYP7A1 activity, was determined in all the experiments 
at 90-min intervals.
Results CYP7A1 activity was up-regulated after treat-
ment with cholestyramine and suppressed after treatment 
with CDCA. There were no differences between -203A and 
-203C allele carriers in the response of enzyme activity to 
both drugs. In the control experiment, -203A allele carriers 
displayed diurnal variation in enzyme activity, whereas CY-
P7A1 activity did not change in -203C allele carriers. These 
results were confirmed by modeling the dynamics of C4 
using polynomial regression.
Conclusion The promoter polymorphism of the CYP7A1 
gene has a pronounced impact on diurnal variation in CY-
P7A1 activity.
Received: January 8, 2016
Accepted: March 20, 2016
Correspondence to: 
Tereza Blahová 
Laboratory for Atherosclerosis 
Research 
Institute for Clinical and 
Experimental Medicine 
Vídeňská 1958-9 
140 21 Prague 4, Czech Republic 
tereza.blahova@ikem.cz
Miluše Vlachová1, Tereza 
Blahová1, Věra Lánská1, 
Martin Leníček2, Jan Piťha1, 
Libor Vítek2,3, Jan Kovář1
1Institute for Clinical and 
Experimental Medicine, Prague, 
Czech Republic
2Institute of Clinical Biochemistry 
and Laboratory Diagnostics, 
1st Faculty of Medicine, Charles 
University in Prague, Prague, Czech 
Republic
34th Department of Internal 
Medicine, 1st Faculty of Medicine, 
Charles University in Prague, 
Prague, Czech Republic
Diurnal variation in cholesterol 
7α-hydroxylase activity is 
determined by the -203A>C 
polymorphism of the CYP7A1 
gene
RECOOP for Common Mechanisms of Diseases 
 
Croat Med J. 2016;57:111-7 
doi: 10.3325/cmj.2016.57.111 
RECOOP for Common Mechanisms of Diseases 112 Croat Med J. 2016;57:111-7
www.cmj.hr
Cholesterol 7α- hydroxylase (CYP7A1) is the key regula-
tory enzyme of the classic bile acid biosynthetic pathway. 
Its activity is subjected to complex feedback regulation in 
order to maintain the bile acid pool (1,2). Enzyme activity 
has been shown to exhibit a distinct diurnal variation in 
rodents (3) and humans (4). The study in humans took ad-
vantage of the fact that CYP7A1 activity in the liver corre-
lated with concentration of 7α-hydroxy-4-cholesten-3-one 
(C4) in plasma, which can be thus used as a reliable marker 
of CYP7A1 activity (5,6). The same authors demonstrated 
that there were two peaks in enzyme activity, the first at 
midday and the second around 10pm (4). In our previous 
study in healthy volunteers carried out between 7am and 
10pm, we reproduced their findings for the midday peak 
(7). However, we noted that enzyme activity displayed very 
high inter-individual variability.
Several polymorphisms have been identified in the regu-
latory regions of the CYP7A1 gene. One of these polymor-
phisms, -203A>C (rs3808607), has been shown to affect 
cholesterolemia and responsiveness of cholesterolemia 
to diet as well as drug treatment (8-13). The mechanisms 
involved have not yet been explained and it is still not 
clear whether this promoter polymorphism can also af-
fect diurnal variation in enzyme activity. Therefore, in this 
case-control study, we investigated whether the course 
of CYP7A1 diurnal activity differed between homozygous 
young healthy male carriers of -203A and -203C alleles of 
the CYP7A1 gene. We also analyzed the effect of short-term 
chenodeoxycholic acid (CDCA) and cholestyramine (a bile 
acid sequestrant) treatments on CYP7A1 activity through-
out the day. These drugs down-regulate and up-regulate 
CYP7A1 activity, respectively.
ParTiciPanTs and MeThods
Participants and study design
Sixteen healthy male volunteers – 8 homozygous for the 
-203A CYP7A1 allele and 8 homozygous for the -203C allele 
– were recruited from among the personnel of both partici-
pating institutions. Both groups were matched with respect 
to age (mean±SD, 25.7 ± 3.4 vs 25.3 ± 3.8 years, respective-
ly). The study design was exactly the same as in our pre-
vious study (7), consisting of three daylong examinations. 
One of these examinations served as a control examina-
tion (without any drug intervention), while the other two 
were used to investigate the effect of short-term adminis-
tration of cholestyramine (Questran®, Bristol-Myers Squibb, 
Prague, Czech Republic, 16 g/d) and chenodeoxycholic acid 
(CDCA; Chenofalk®, Dr Falk Pharma GmbH, Freiburg, Germa-
ny, 1-1.5 g/d depending on the weight of the participant). 
One day before each of these examinations (Day 0), the first 
blood sample was drawn at 7am, after which participants 
received food for the whole day to standardize their intake 
before the study. On the day of examination (Day 1), the first 
blood sample was drawn again at 7am and the blood sam-
ples were then collected at 90-min intervals for 15 h until 
10pm. Again, participants received food for the whole day 
and were required to eat at exactly defined intervals (break-
fast at 7.15am, snack at 9.45am, lunch at 12.30pm, snack at 
3.30pm, and dinner at 5.30pm). The amount of food was cal-
culated to cover their energy requirements – ~ 160 kJ/kg/d 
– and the diet was relatively low in fat (25% of energy in-
take). When the examination included drug administration, 
the drugs were given on Day 0 and Day 1. Cholestyramine 
was given in two doses on both days – one with breakfast, 
the other with dinner. Due to differences in pharmacoki-
netics, CDCA treatment was started with dinner on Day 0, 
and on Day 1 was given in two doses at the same time as 
cholestyramine. The order of the examinations was random-
ized and carried out at three-week intervals at a minimum. 
The study protocol adhered to the principles of the Declara-
tion of Helsinki, was approved by the Ethics Committee of 
the Institute for Clinical and Experimental Medicine, and all 
of the participants gave their informed consent.
Genotyping and biochemical analyses
Determination of the -203A>C genotype of CYP7A1 was 
carried out as described earlier (14). Plasma cholesterol and 
triglyceride (TG) concentrations were determined using 
enzymatic kits from Roche Diagnostics GmbH, Mannheim, 
Germany. Concentration of C4 was determined by HPLC as 
described earlier (15).
statistics
ANOVA for repeated measures was used to determine 
whether the concentrations of cholesterol, TG, and C4 
varied throughout the experiments. ANOVA for repeated 
measures with one grouping factor (genotype) was used 
to determine whether there were any differences in the 
course of the concentration changes between carriers of 
-203A and -203C alleles. The data for analysis were logarith-
mically transformed if they did not pass the Shapiro-Wilk 
normality test. However, ANOVA results for logarithmically 
transformed and nontransformed data were comparable. 
Presented results of ANOVA are from nontransformed data. 
The dynamics of C4 concentration changes in the control 
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experiment was modeled using polynomial regression of 
order 5. The JMP 10.0.0 statistical software (SAS Institute, 
Inc., Cary, NC, USA) was used for analyses. P-value lower 
than 0.05 was considered statistically significant.
resuLTs
Homozygous carriers of A and C allele did not differ in plas-
ma cholesterol (4.70 ± 0.91 vs 4.73 ± 0.65 mmol/L, respec-
tively, P = 0.941, t test) and plasma TG levels (1.78 ± 1.03 vs 
1.28 ± 0.39 mmol/L, respectively, P = 0.231, t test). The -203C 
allele carriers had significantly increased BMI (27.2 ± 3.3 vs 
23.4 ± 3.5 kg/m2, P = 0.048, t test).
As expected, CYP7A1 activity – estimated on the basis 
of C4 concentration measurement at 7am – rose sev-
eral-fold after one-day treatment with cholestyramine, 
dropped by a half after one-day treatment with CDCA, 
and did not change in the control experiment in all par-
ticipants (Table 1).
During the CDCA treatment, there were no changes in 
plasma C4 concentrations on the day of the study in both 
-203A and -203C allele carriers (Figure 1) (P = 0.373 and 
0.208, respectively). Importantly, no effect of the geno-
type on the course of C4 concentrations was detected 
(P = 0.221).
TaBLe 1. Fasting concentrations and areas under curve (auc) of cholesterol, triglyceride (TG), and 7α-hydroxy-4-cholesten-3-one (c4) 
in homozygous -203a and -203c CYP7A1 allele carriers (mean ± standard deviation). 0 – control experiment, cdca – experiment with 
short-term treatment using chenodeoxycholic acid, Q – experiment with short-term treatment using cholestyramine
-203aa carriers -203cc carriers
0 cdca Q 0 cdca Q
Cholesterol Day 0 [mmol/L]   4.69±1.08   4.88±0.95    4.83±0.96   4.70±0.65   4.44±0.75    4.81±0.44
Day 1 [mmol/L]   4.56±1.10   4.98±1.09    4.89±1.10   4.71±0.62   4.63±0.61    4.44***±0.42
AUC [mmol*h/L]  65.7±15.6  70.2±14.6   67.9±15.0  68.0±9.2  67.7±9.4   63.2±7.0
TG Day 0 [mmol/L]   1.48±0.84   1.58±0.82    1.71±1.26   1.54±0.65   1.40±0.73    1.33±0.41
Day 1 [mmol/L]   1.39±0.82   1.66±0.96    1.65±0.85   1.70±1.03   1.70±0.72    1.85*±0.65
AUC [mmol*h/L]  24.9±13.3  28.9±15.0   24.0±12.9  29.0±16.9   27.4±9.2   28.1±14.3
C4 Day 0 [μg/L]  16.0±9.1  19.9±13.2   13.9±8.7  22.9±16.6  36.1±32,8   28.2±21.1
Day 1 [μg/L]  20.3 a,b±15.9   9.6 b,**±9.6   70.2 a,***±27.3  24.7 d,e±23.1  15.6 e,**±18.8  111.3 d,**±70.1
AUC [μg*h/L] 326 b±94 131 c±65 1317 a±312 270 e±168 112 e±71 1830 d±808
*,**,***P < 0.05, P < 0.01, P < 0.001 for day 1 vs day 0; a,b,c the same letters are assigned to the experiments that do not differ in -203a allele carriers 
where differences between experiments are detected by anoVa; d,e,f the same letters are assigned to the experiments that do not differ in -203c 
allele carriers, where differences between experiments are detected by anoVa.
FiGure 1. The course of 7α-hydroxy-4-cholesten-3-one (c4) concentrations throughout day 1 after short-term administration of 
cholestyramine and cdca and in the control experiment. 0 – control experiment, cdca – experiment with short-term treatment us-
ing chenodeoxycholic acid, Q – experiment with short-term treatment using cholestyramine; -203aa, -203cc – homozygous carriers 
of the -203a and -203c allele of the CYP7A1 gene, respectively.
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During the cholestyramine treatment, C4 concentrations 
significantly increased during the day in -203A allele car-
riers (P = 0.004). A similar but not significant trend was ob-
served in -203C allele carriers (P = 0.074). However, the gen-
otype had no effect on the course of C4 concentrations 
throughout the day (P = 0.659).
In the control experiment, plasma C4 concentrations sig-
nificantly varied during the day in -203A allele carriers 
(P = 0.001) with a peak around 1pm. On the other hand, 
C4 concentrations did not change during the day in 
-203C allele carriers. Moreover, there was a trend for the 
effect of the genotype on the course of C4 concentrations 
(P = 0.092). These results suggest that there may be differ-
ences in the diurnal variation in CYP7A1 activity between 
homozygous -203A and -203C allele carriers. To test such 
a hypothesis, we modeled the dynamics of C4 concentra-
tion changes using fifth order polynomial regression (Fig-
ure 2, Table 2). The regression equation coefficient of order 
2 significantly differed from zero only in -203A allele carri-
ers, but not in those carrying the -203C allele. Important-
ly, the coefficients of the second and fourth order of cor-
responding regression equations were different between 
carriers of -203A and -203C alleles.
CDCA treatment had no effect on cholesterol and TG con-
centrations for all of the participants. Administration of 
cholestyramine resulted in an 8% decrease in cholester-
ol concentration and a 39% increase in triglyceridemia in 
homozygous -203C allele carriers. No such effect was ob-
served in -203A allele carriers. However, the AUCs of both 
cholesterol and TG on Day 1 did not differ between -203A 
and -203C allele carriers (Table 1).
discussion
This small study of healthy volunteers showed that ho-
mozygous participants carrying the -203A allele of the CY-
P7A1 displayed diurnal variation in CYP7A1 activity, peak-
ing at midday. No diurnal variation in CYP7A1 activity was 
observed in homozygous carriers of the -203C allele.
Such findings were further corroborated by modeling the 
dynamics of C4 concentration changes using polynomial 
regression of order 5. Importantly, we found that the coef-
ficients of the second and fourth order (a2 and a4) of the 
TaBLe 2. coefficients of the polynomial regression equation 
(a0, a1, a2, a3, a4, a5) of order 5 for the relationship between 
7α-hydroxy-4-cholesten-3-one (c4, µg/L) concentration and 
time of day (t, hours) in -203a and -203c allele carriers. c4 = a0 





estimates are mean (se).
-203aa carriers -203cc carriers
coefficient coefficient estimate coefficient estimate
a0 60.20 (8.96)** 33.19 (4.36)***
a1 -4.258 (1.158)*  -1.918 (0.563)*
a2 -0.6564 (0.2174)*  -0.1563 (0.1058)
†
a3  0.2135 (0.0733)*   0.1021 (0.0357)*
a4  0.0088 (0.0037)   0.0032 (0.0018)
†
a5 -0.0025 (0.0010)  -0.0014 (0.0005)*
*,**,***P < 0.05, P < 0.01, P < 0.001 for the coefficient estimate being 
equal to zero.
†P < 0.05 for coefficient estimates being equal for homozygous carri-
ers of the -203a and -203c alleles. The equation is valid for the interval 
between 7am until 10pm.
FiGure 2. The course of 7α-hydroxy-4-cholesten-3-one (c4) concentrations throughout day 1 as modeled using polynomial regres-
sion of order 5. -203aa, -203cc – homozygous carriers of the -203a and -203c allele of the CYP7A1 gene, respectively.
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corresponding regression equations were different in the 
carriers of -203A and -203C alleles. It should be pointed out 
that only functions with nonzero coefficients of odd order 
(2 and 4 in our case) display the presence of a peak, while 
coefficients of even order do not. This strongly supports 
the idea that the course of C4 concentrations differs be-
tween homozygous carriers of the two alleles – the peak of 
CYP7A1 activity can be observed only in A allele carriers.
It has been shown that CYP7A1 activity in humans has two 
peaks (4) – one in the early afternoon and the second be-
fore midnight – but due to the design of our study, we can 
make conclusions only about the first peak. Interestingly, 
there is no clear mechanistic explanation for the midday 
peak. It has been demonstrated that such a peak appears 
both in participants who eat normally and those who are 
fasting before midday (4). Such an increase is thus unlikely 
to be associated with food intake. Interestingly, CYP7A1 ac-
tivity then decreases rapidly only in subjects who eat nor-
mally and not in those who are fasting. This may suggest 
that increased intrahepatic flux of bile acids, and especially 
intestinal fibroblast growth factor-19 (FGF-19) secretion, af-
ter a meal are involved in dampening the peak of CYP7A1 
activity (16).
Using a dual luciferase reporter assay with promoter 
fragments (-716 to +14) of both variants of the CYP7A1, 
we confirmed the previous findings that in HepG2 cells 
the -203C allele was expressed five times more than the 
-203A allele (17). However, we did not see any differences 
in the effects of bile acids, cortisol and dexamethasone, 
insulin, and peroxisome proliferator-activated receptor α 
(PPARα) agonists (fenofibrate and WY-14643) on the ex-
pression of both promoter variants (Vlachová M, Blahová 
T, unpublished data). This may suggest that factors other 
than those associated with food intake may play a role 
in the regulation of CYP7A1 activity throughout the day. 
Furthermore, we tried to find whether any transcription 
factor binds differently to both variants of the promoter 
surrounding -203 position using in silico analysis (Tran-
scription Element Search System, Vlachová M, unpub-
lished data). Except of putative new binding site for a glu-
cocorticoid receptor [AGAA-203CT] in -203A allele (which 
does not seem to be functional based on dual luciferase 
data), no other differences between the promoter vari-
ants were found. No differences in the presence of puta-
tive binding sites were found also in five other polymor-
phisms (rs1023652, rs1023649, rs3903445, and rs3824260) 
that are in a tight linkage disequilibrium with -203A>C 
variant (rs3808607).
The diurnal variation in CYP7A1 activity and Cyp7a1 gene 
expression has been extensively studied in mice and rats 
and it was demonstrated that Cyp7a1 expression in mice 
was controlled by several clock genes (18-22). It remains to 
be determined whether clock genes also play a role in the 
regulation of bile acid synthesis in humans.
Given that some participants do not display diurnal varia-
tion, it is surprising that this has remained unnoticed so 
far. This is likely due to the small sample size of studies in-
vestigating circadian variation in CYP7A1 activity (4,16), 
and it cannot be excluded that -203C allele carriers were 
not studied. This can even suggest that the effect of more 
prevalent -203A allele is dominant and heterozygous carri-
ers display diurnal variation in CYP7A1 activity.
It must be also stressed that the -203A>C polymorphism 
may not be the one responsible for observed differences in 
circadian changes in CYP7A1 activity. It has been demon-
strated that this polymorphism is in close linkage disequi-
librium with several other polymorphisms in the CYP7A1 
(23). In the Caucasian population (the only population in 
which studies of diurnal variation in CYP7A1 have been 
carried out), the -203A and -203C alleles are considered to 
be markers of haplotype blocks spanning 14 kb from the 
proximal promoter to the 3’-downstream of the CYP7A1. 
Therefore, either of the polymorphisms included in these 
haplotype blocks may be responsible for the observed dif-
ferences in diurnal variation in the enzyme activity.
The fact that C allele carriers cannot increase the CYP7A1 
diurnal activity might explain their hyperresponsiveness to 
dietary cholesterol and saturated fat as observed in previ-
ous studies (10-12). They might be unable to eliminate the 
excess of dietary cholesterol through its transformation 
into bile acids as efficiently as A allele carriers, and their 
cholesterolemia might be augmented.
The major limitation of this study, apart from the small 
sample size, is the lack of night blood sampling. In future 
studies, 24-hour monitoring and inclusion of heterozy-
gous individuals should be undertaken. It should be kept 
in mind that C4 is only a surrogate marker of CYP7A1 ac-
tivity – however, it is hard to overcome such a limitation in 
human studies. Additionally, -203C carriers in our cohort 
had higher BMI.
In conclusion, we demonstrated that the -203A allele of 
the CYP7A1 was associated with pronounced diurnal varia-
tion in CYP7A1 activity, whereas the -203C allele was not. It 
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remains to be determined whether differences in diurnal 
variation in enzyme activity between carriers of the -203A 
and -203C alleles can explain the differential effects of these 
variants on cholesterolemia and its responsiveness to diet.
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